Starting diabetes medicines earlier, blood thinners people go without, and a shorter hepatitis C cure
Five updates published between September 28 and October 2 translate a new type 2 diabetes consensus, a blood-thinner care gap, the ACC's diet guidance, an oral GLP-1 trial, and a shorter hepatitis C cure into practical questions for your next appointment.
Five documents published between September 28 and October 2, 2026 touch each of the three conditions this brief follows. The American Diabetes Association and the European Association for the Study of Diabetes issued a new consensus report on managing type 2 diabetes, and it calls for using two drug families earlier than many people start them today. The American Heart Association described how often people with an irregular heartbeat, a past blood clot, or narrowed leg arteries are left taking less blood thinner than they were prescribed. The American College of Cardiology published a statement on nutrition that judges eating by the whole pattern rather than by single nutrients. A large trial put an experimental oral GLP-1 pill up against insulin in people with type 2 diabetes and heart or kidney disease. And a study in India found that eight weeks of hepatitis C treatment cured people as reliably as the usual twelve.
The summaries below are background for your next appointment. Your clinician knows your history, your test results, and your current prescriptions, and treatment decisions belong in that conversation.
Quick view
| Update | What changed | Who may care | Action window | Appointment question |
|---|---|---|---|---|
| Type 2 diabetes managed more broadly | The ADA and EASD published a consensus report on October 2 that widens type 2 diabetes care beyond blood sugar to the risk of related heart and kidney conditions, and calls for earlier use of SGLT2 inhibitors and GLP-1 medicines — potentially from the day of diagnosis. 1 | Adults with type 2 diabetes, especially those who also have heart disease, heart failure, or chronic kidney disease | At your next diabetes visit, or before a new medicine is chosen | "I have type 2 diabetes along with heart or kidney disease — should I be on an SGLT2 inhibitor or a GLP-1 medicine, and could it start sooner than we planned?" |
| Blood thinners taken less than prescribed | An AHA scientific statement published October 1 describes how often people with atrial fibrillation, venous blood clots, or peripheral artery disease take no blood thinner or a dose below the evidence-based one, and links that gap to more strokes, clots, and deaths. 2 | Anyone prescribed a blood thinner, and their caregivers — particularly older adults, people who are frail or have memory trouble, and those facing cost or pharmacy barriers | At your next visit, before any dose change | "I take a blood thinner — is the dose right for me, and what should I do if I am worried about bleeding?" |
| Diet quality ahead of single nutrients | A new ACC scientific statement published September 30 lays out the evidence for judging eating by the whole pattern: more minimally processed plant foods, fiber, and unsaturated fats; less sodium, sugar-sweetened drinks, processed meats, and ultra-processed food. 3 | Anyone managing cardiovascular disease, type 2 diabetes, obesity, or chronic kidney disease, including people taking a GLP-1 medicine | This week | "Can we review my overall eating pattern, and can I get a referral to a dietitian or a food-as-medicine program?" |
| An oral GLP-1 pill measured against insulin | In the ACHIEVE-4 trial published September 30, 2,749 adults with type 2 diabetes at high heart risk took either an experimental oral GLP-1 pill (orforglipron) or injected insulin glargine; over a median two years the pill was no worse on the combined measure of heart death, heart attack, stroke, and unstable-angina hospitalization. 4 | Adults with type 2 diabetes and heart or kidney disease who may need to add an injectable | At your next visit if insulin is being considered | "If my blood sugar needs more than pills, what are the options besides insulin, and how do their side effects compare?" |
| A shorter hepatitis C cure | In the RESOLVE trial published September 30, 880 people in India with hepatitis C and no cirrhosis were cured at the same rate on eight weeks of sofosbuvir-velpatasvir as on the standard twelve. 5 | People with chronic hepatitis C who have not yet been treated and have no cirrhosis | At your next visit, before treatment starts | "I have hepatitis C without cirrhosis — can I be treated for 8 weeks instead of 12?" |
1. Type 2 diabetes care widens beyond blood sugar
The American Diabetes Association and the European Association for the Study of Diabetes have updated the consensus report they share on managing type 2 diabetes in adults. The report appeared on October 2 in Diabetes Care and Diabetologia, and it replaces the 2022 edition of a document first published in 2006. 16
A consensus report is a different kind of document from a formal clinical practice guideline. A panel of specialists reads the evidence and agrees on what good care looks like; the result is expert judgment, which your own clinician weighs against your history.
This edition broadens the target of treatment. Where earlier versions concentrated on lowering blood sugar, the 2026 report frames type 2 diabetes as a condition that carries the risk of several long-term problems at once, and it asks care teams to manage them together. Three shifts stand out.
The first is lifestyle, named as a foundation of care: healthy eating, a full day's activity that includes sleep, and avoiding tobacco and substance use. The second is psychological support and weight management, treated as standing parts of care rather than extras. The third is timing. The report advocates earlier use of two drug families — SGLT2 inhibitors, which lower blood sugar partly by pushing glucose out in the urine and which protect the heart and kidneys, and GLP-1 medicines such as semaglutide, which mimic a gut hormone and do the same. It suggests these medicines can be considered from the day of diagnosis for organ protection, and for people who already have cardiovascular disease, chronic kidney disease, or heart failure, it suggests the two families be used in combination earlier than current practice often manages.
Ask at your next visit: "I have type 2 diabetes along with heart or kidney disease — should I be on an SGLT2 inhibitor or a GLP-1 medicine, and could it start sooner than we planned?"
2. Many people who need blood thinners take less than prescribed
Blood thinners — anticoagulants and antiplatelets — are a cornerstone of care for several vascular conditions, and on October 1 the American Heart Association published a scientific statement in Circulation on a gap that runs through all of them. The statement gives that gap a name: antithrombotic undertreatment. 2
The name covers four situations: the medicine is never prescribed though it is clinically indicated, the prescribed dose sits below the evidence-based one, drug interactions or dose changes push the drug's level below the therapeutic range, or the patient takes it less often than prescribed. The statement surveys three groups where this happens — people with atrial fibrillation, an irregular heartbeat that raises stroke risk; people with venous thromboembolism, clots that form in the veins and can travel to the lungs; and people with peripheral artery disease, narrowed arteries in the legs.
In atrial fibrillation, the picture is well documented. Undertreatment clusters among older adults, people who are frail or have cognitive impairment, and racial and ethnic minority populations. Direct-acting oral anticoagulants, the modern class of blood thinners, given at too low a dose brought no reduction in bleeding, and they were linked to more clots, strokes, and deaths — which is to say the smaller dose bought less safety without returning any of the protection. In venous thromboembolism, treatment is omitted or underdosed despite clear guidance for both the acute phase and the extended phase. In peripheral artery disease, antiplatelet medicines are underused, and so is a combined approach that adds a low dose of a second blood thinner.
Those gaps carry a cost: more ischemic strokes, more recurrent clots, more heart and limb events, and more deaths. The statement attributes part of the problem to misread bleeding risk, part to health-care access, and it proposes what it calls antithrombotic stewardship — coordinated, team-level attention to getting the right drug, at the right dose, into the right patient.
Ask at your next visit: "I take a blood thinner — is the dose right for me, and what should I do if I am worried about bleeding?"
3. The whole pattern of eating matters more than any single nutrient
On September 30 the American College of Cardiology published a scientific statement in the Journal of the American College of Cardiology on nutrition and heart health, and its central claim is a shift in how the field reads the evidence. Judging a diet nutrient by nutrient has given way to judging the whole pattern — overall diet quality, the foods chosen, and how heavily they are processed. 3
The statement gathers the recommendations the evidence supports: replace saturated fats with unsaturated fats; raise dietary fiber and whole grains; cut sodium and ultra-processed foods, with sugar-sweetened drinks and processed meats singled out; and favor water and unsweetened drinks over sugary ones, with alcohol generally limited. Mediterranean, DASH (a blood-pressure-lowering pattern), vegetarian, and other plant-rich diets show favorable effects on blood pressure, cholesterol, blood sugar, and weight, and are consistently linked with lower rates of cardiovascular disease and death.
Two parts of the statement speak directly to patients. One is food security: the authors note that availability, affordability, accessibility, and use of nutritious food shape what people can actually eat, and they call for dietitian counseling, medical nutrition therapy, and Food Is Medicine programs to reach more people. The other concerns GLP-1 medicines. The statement acknowledges the weight loss and heart benefits these drugs produce, and stresses that a nutrient-rich, high-quality diet stays important during treatment — the medication changes appetite, and it does not supply the nutrients a body still needs.
Ask at your next visit: "Can we review my overall eating pattern, and can I get a referral to a dietitian or a food-as-medicine program?"
4. An oral GLP-1 pill held its own on heart safety against insulin
Injections have been the only way to take a GLP-1 medicine — until now, at least in trials. Orforglipron is an experimental oral GLP-1 pill, and the question hanging over it was whether a non-peptide version taken by mouth would protect the heart the way the injected drugs do. On September 30 the Lancet published ACHIEVE-4, which compared the pill with insulin rather than with a placebo. 4
The trial ran at 317 sites in 16 countries and enrolled 2,749 adults with type 2 diabetes at increased cardiovascular risk: their HbA1c sat between 7.0 and 10.5 percent, their body mass index was 25 or higher, and they took up to three glucose-lowering medicines. About 86 percent already had cardiovascular disease and about 38 percent had chronic kidney disease. Half were assigned a once-daily oral dose of orforglipron, and half a once-daily injection of insulin glargine, both continued for about two years.
The result concerned the combined measure of cardiovascular death, non-fatal heart attack, non-fatal stroke, and hospitalization for unstable angina. It occurred in 4.2 percent of the orforglipron group and 5.0 percent of the insulin group, a hazard ratio of 0.84 with a confidence interval from 0.59 to 1.20. That range crosses 1.0, so the trial's claim stops at showing the pill was no worse than insulin on heart risk.
The side-effect profiles differed in both directions. Gastrointestinal symptoms were far more common with orforglipron, reported in 62.1 percent of the group against 14.2 percent on insulin. Clinically significant low blood sugar was less common with the pill, 6.8 percent against 19.2 percent. Deaths over the study ran 1.4 percent against 3.2 percent, and the investigators judged every death but one unrelated to treatment. Eli Lilly, which is developing orforglipron, funded the trial.
Someone with type 2 diabetes and heart or kidney disease who is weighing an injectable now has one more comparison to bring to the conversation — with the caveat that orforglipron is still under review and not yet available.
Ask at your next visit: "If my blood sugar needs more than pills, what are the options besides insulin, and how do their side effects compare?"
5. A shorter hepatitis C cure held up in a head-to-head trial
Hepatitis C, a viral infection of the liver, can now be cured with a course of direct-acting antiviral pills. For people without cirrhosis, the standard course has been twelve weeks of sofosbuvir-velpatasvir. On September 30 the Lancet published RESOLVE, a trial that asked whether eight weeks would cure people just as reliably. 5
The trial ran at five publicly funded hospitals in India and assigned 880 adults with chronic hepatitis C and no cirrhosis, none of whom had been treated before, to eight weeks or twelve weeks of treatment. Its measure of success was a sustained virological response at twelve weeks, meaning no detectable virus three months after the pills stopped.
Among the people who completed their assigned course, 98.8 percent of the eight-week group and 99.0 percent of the twelve-week group cleared the virus — a difference of 0.2 percentage points, inside the margin the trial had set for calling the shorter course just as good. Counting everyone assigned to a group regardless of whether they finished, the eight-week group did slightly better, 93.5 percent against 91.8 percent. No participant had a drug-related serious adverse event or stopped treatment because of a side effect. The Indian Council of Medical Research funded the study.
Two limits travel with the result. The trial ran in a single country, so schedules and coverage in the United States may move at their own pace. And it enrolled only people with no cirrhosis who had never been treated, which is the group this shorter course was tested in.
Ask at your next visit: "I have hepatitis C without cirrhosis — can I be treated for 8 weeks instead of 12, or does my situation need the full course?"
Questions to take to your appointment
- "I have type 2 diabetes along with heart or kidney disease — should I be on an SGLT2 inhibitor or a GLP-1 medicine, and could it start sooner than we planned?"
- "I take a blood thinner — is the dose right for me, and what should I do if I am worried about bleeding?"
- "Can we review my overall eating pattern, and can I get a referral to a dietitian or a food-as-medicine program?"
- "If my blood sugar needs more than pills, what are the options besides insulin, and how do their side effects compare?"
- "I have hepatitis C without cirrhosis — can I be treated for 8 weeks instead of 12, or does my situation need the full course?"
References
- 1
- 2
- 3
- 4
- 5
- 6
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.